Find These Stocks Before Wall Street Does

Seeking stocks that others ignore, shun, or simply forget gives individual investors like you an edge over the professionals. Getting in before Wall Street discovers them -- or rediscovers them -- means you can stake a claim before they start taking off. 

Here we check out companies with minimal analyst coverage at best, and then pair our list with the opinions of the Motley Fool CAPS community. A stock that garners CAPS' top ratings, but hasn't yet caught analysts' attention, could be your next home run investment.

Stock

CAPS Rating (out of 5)

Wall St. Picks

Wall St. Bullish Sentiment

Est. EPS Growth Next Year

Amarin (Nasdaq: AMRN  ) **** 5 100% 115%
Cellcom Israel (NYSE: CEL  ) **** 3 67% (7%)

Source: Motley Fool CAPS.

Remember, without much analyst support, you'll have to do more digging on your own to see whether these stocks deserve a spot in your portfolio, so don't just buy or sell them based solely on their appearance here. 

Hiding in plain sight
A couple of weeks ago, I got cheeky and noted developers of fish oil therapies like Amarin and GlaxoSmithKline would be put out if a new study that found fish oil did nothing to prevent heart attacks held up under closer scrutiny. I pointed out GSK generates a billion dollars annually from its treatment Lovaza, and many analysts expect Amarin's AMR101 to steal a lot of Lovaza's market share if and when it hits the market because of its efficacy and lower risks.

My apples-to-oranges comparison -- or as stereoandy commented, "apples to gorillas" -- was a bit off the mark. The cruder compounds used in the study apparently can't be compared to either Lovaza or AMR101 because "Lovaza is a much more highly purified concentrate, and AMR101 is an even higher concentration of pure EPA with no DHA (the element in Lovaza believed to elevate ldl)." EPA is eicosapentaenoic acid and DHA is docosahexaenoic acid, but I'll admit the actual science makes my eyes glaze over.

Amarin seems to have a real winner on its hands and with possible FDA approval coming around next month, I'll be maintaining my outperform rating on CAPS -- and I won't be so quick to be cheeky. Let me know in the comments box below or on the Amarin CAPS page if the doubters are just peddling snake oil, then add the biotech to the Fool's free, personalized stock-tracking service to be alerted immediately when the FDA releases its decision.

Hung up on growth
There's been a lot of static in the Israeli cellphone arena as new players offering lower prices roil the market. Cellcom Israel, the country's largest cellphone provider, has lost nearly three-quarters of its value over the past year as new entrants came into the marketplace and are offering discounted plans for talk, text, and Internet.

Like Verizon, Sprint (NYSE: S  ) , and T-Mobile, Cellcom has had to react to the low-price plans by cutting its own prices. U.S. telecoms have cut prices, too, or introduced prepaid services, such as Sprint did with Boost Mobile, to compete with MetroPCS (NYSE: PCS  ) and others.

The results of the new competitive landscape showed up in Cellcom's quarterly earnings report that saw profits plummet 43% from last year. The loss in the stock's value will also cause it to get dropped from the MSCI Israel Index. Second-place Partner Communications (Nasdaq: PTNR  ) also witnessed a huge drop in profits, and it has withdrawn plans to issue a dividend. Apparently after being coddled by the Israeli government for so many years, the state is now issuing new licenses and just five entrants have upset the apple cart.

So it's hard to see what the investing thesis might be for Cellcom. Although it pays a dividend that currently yields 14.5%, free cash flow plummeted 64%, which suggests the payout is going to be unsustainable.

Yet 96% of the CAPS All-Stars rating the cellular operator believe it can still beat the Street. I'm not so sure and marked it to underperform the broad indexes, but let me know on the Cellcom Israel CAPS page or in the comments below what will have this company turn around, then add it to your watchlist to be alerted of any changes.

Swing for the fences
If health care and biotechs like Amarin pique your interest, find out the one health care stock counting on an acquisition to get solid returns in the Fool's free report "Discover the Next Rule-Breaking Multibagger." But hurry; it's available for a limited time only!

Fool contributor Rich Duprey holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (3) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 22, 2012, at 3:48 PM, skm1965 wrote:

    Your comment about Amarin:

    1) Amarin's presentation showed the results of JELIS study in Japan by Epadel--very nice(even though Japanese eat lot of fish).In USA,results of REDUCE-IT should be even better-for Cardiac events. I am surprised that Mochida corp. did not sell in USA--as their sales in Japan are 500 million$ with Japan population less than half of USA.

    So I am very positive about the benefits of purified Fish oil.I take 3 pills a day and have noticed sharp drop in Triglcerides and my sugar level also.

    2) If link to diabetic patients-benefitting from Amarin's product is established--then means more sales.

    3) There are other applications --read their patents language--helping Psych.problems

    4) Getting stronghold in patents is key?

    5) Most security analysts who follow AMRN are very bullish--THEY ARE NOT ALL -not misguided.

    6) CEO selling shares--is part of annual salary addition.But people take different meaning.Think that there is no one trying to buy them.

    7) I think 20$ price target is likely in 12 months--30$ if some one wants to acquire them which will happen after they launch the product and get more patents.(aug.date for one key patent is coming up.)

    8) FDA approval is very likely in July for one group of people.

  • Report this Comment On June 22, 2012, at 4:36 PM, yazzbro wrote:

    skm the $20 price target will most likely come a lot sooner than 12 months.(Why 12 months?) It will probably be $20 or higher around the FDA approval. If it receives the '889 patent it will go higher than that. An acquasition will likely be a minimum of $35 a share and it will all happen way sooner than a year from now. AMRN doesn't have time to wait a whole year.

  • Report this Comment On June 22, 2012, at 9:31 PM, InsouciantTrader wrote:

    AMRN timeline is pretty simple: they get approved in July (or September w/ delay), they have announced that they launch the drug in early 2013, and that they'll make a decision on commercialization near the start of October. So if they're going to sell out (and they should), they will likely have a small window of time between approval and commercialization to decide on that path.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1921801, ~/Articles/ArticleHandler.aspx, 11/24/2014 1:16:05 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement